MI Member Institutions

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions.

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation.

“From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said Raphael Hofstein, president and CEO of MaRS Innovation. “Our partnership with GSK Canada furthers Ontario’s position as a major international research hub by providing much needed capital to fund exciting drug discovery and development technologies and bridging the gap to successful commercialization.

“Launching this development fund is also part of a global trend where government, researchers and industry are partnering at the early stage of translational research with an eye to achieving global impact and improving patient care,” Hofstein added.

Continue Reading

York University becomes 17th Member of MaRS Innovation

MaRS Innovation to act as commercialization agent for York’s life sciences and technology discoveries, leveraging new potential for York’s existing $70 million in research initiatives

TORONTO, May 9, 2011 – York University has become the latest member of MaRS Innovation, the commercialization agent for many leading Toronto-based universities, hospitals and research institutes.

Stan Shapson, vice-president Research & Innovation, York University
Stan Shapson, Vice-President Research & Innovation, York University

“York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a year. Joining MaRS Innovation allows us to deliver the most competitive commercialization services to the researchers making these discoveries. We’re confident that membership in MaRS Innovation will boost that number and accelerate the commercialization of York’s most promising research.”

Earlier this year, York University launched its Innovation York office. Based in York Region, Innovation York works with other partner organizations in the Markham Convergence Centre to build upon research partnerships between York researchers and life science and technology companies based in York Region and the Greater Toronto Area. It’s also making York’s research and infrastructure more accessible to industry, government agencies and community partners.

Continue Reading

How VitalHub Corp. Uses iPhones® To Help Health Care

VitalHub Corp Logo: Patient information made easyTORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp..

The unique start-up company was spun-off from mobile health technologies developed  Toronto’s Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector.

MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto’s leading universities, hospitals (such as Mount Sinai) and research institutions. This funding commitment rounds out a sizeable seed round of financing for VitalHub.

Continue Reading

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread.

University of Toronto
University of Toronto

Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 only
 stop 
the 
infections 
at
 wound
sites, 
but
 also
 has
 the
 potential 
to
speed
 up
 wound‐healing.

Still,
 the
 technology
 may
 have
 stayed
 on
 the
 shelf,
 even
 with
 three
 years
 worth
 of
 data
 demonstrating
 therapeutic
 relevance.
 The
 ultimate
 success
 of
 the
 technology
 is
 due
 to
 an
 effective
 collaboration
 between
 Dr.
 Lee,
 the
 Innovations
 and
 Partnerships
 Office
 (IPO)
 at
 U
 of
 T
 and
 MaRS
 Innovation (MI).
 Lee
 worked
 with
 IPO
 and
 MI to
 formulate
 a
 development
 plan
 in
 consultation
 with 
numerous 
industry
 advisors.

Continue Reading

MaRS Innovation selects University of Toronto’s Diabetic Wound Healing Technology as second commercialization opportunity

University of TorontoTORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.

“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally,” said Dr. Raphael (Rafi) Hofstein, president and CEO of MaRS Innovation.

Continue Reading

MaRS Innovation selects Mount Sinai Hospital’s umbilical cord stem cell technology as first commercialization opportunity

Mount Sinai Logo (Bright Minds. Big Hearts. The Best Medicine.)TORONTO (June 29, 2009) – MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.

Raphael Hofstein, president and CEO MaRS Innovation
Dr. Raphael Hofstein, president and CEO of MaRS Innovation

“With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Raphael (Rafi) Hofstein, President and CEO of MaRS Innovation.

The technology – invented by Mount Sinai scientists Dr. Ian Rogers and Dr. Robert Casper – offers a proprietary method to create multi-potent stem cells (MPSCs) from human umbilical cord blood. With preclinical data demonstrating efficacy of MPSCs in diabetes, peripheral vascular disease (a complication of diabetes that can lead to amputation) and neurological conditions, the technology has significant potential to address multiple unmet medical needs.

Continue Reading

Quick Links

Contact Us

Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca

© CopyrightTIAP 2024 - All Rights Reserved | Site Map | CASL Policy | Privacy Policy | AODA Compliance
Twitter Linkedin
Back To Top